Fig. 1 · Structure

Documents & Downloads

BIIB021

Cat. No. A10143 CAS 848695-25-0

HSP90 inhibitor

BIIB021 is an oral fully synthetic Hsp90 inhibitor that selectively and potently inhibits the molecular chaperone Hsp90 thereby inhibiting the proper assembly of multiple oncogenic proteins involved in tumor growth and survival.

In Stock

Publications for BIIB021

7 publications citing this product

  1. Nazan Gökşen Tosun, .et al. , Breast Cancer Res Treat, 2025, Apr;210(2):493-506 PMID: 39779635
  2. Aydemir Asdemir, .et al. , Naunyn Schmiedebergs Arch Pharmacol ., 2024, Jan 19 PMID: 38240781
  3. Celia Rouges, .et al. , Microorganisms, 2023, Nov 22;11(12):2837 PMID: 38137982
  4. C M Güven, .et al. , Eur Rev Med Pharmacol Sci, 2023, Aug;27(15):7299-7308 PMID: 37606138
  5. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  6. Ting-Yu Chang, .et al. , Biomed Pharmacother, 2021, Jun;138:111485 PMID: 33740521
  7. Hiroki Murano, .et al. , Plant Biotechnol Rep, 2017, 11:107-113

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

BIIB021 binds the N-terminal domain of Hsp90α. A fluorescence-polarization assay using recombinant human Hsp90α and a FITC-geldanamycin probe reported an IC50 of 0.029 μM. In a separate ITC experiment with the mouse Hsp90α N-terminal domain, the reported KD was 0.0083 µM at 25 °C. These values describe different binding measurements. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
HSP90 Ki 1.7 nM
HSP90 EC50 38 nM

Cellular Effect

Cell Line Activity Value Description Reference
4T1 IC50 0.55 μM Anticancer activity against mouse 4T1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay [PMID: 34864330]
A549 GI50 0.26 μM Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay [PMID: 32683166]
A549 GI50 0.26 μM Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay [PMID: 33934008]
A549 GI50 0.33 μM Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay [PMID: 32058238]
A549 GI50 0.33 μM Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay [PMID: 29567459]
HCT-116 GI50 0.15 μM Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay [PMID: 32683166]
HCT-116 GI50 0.15 μM Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay [PMID: 29567459]
HCT-116 GI50 0.227 μM Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 30385226]
HCT-116 GI50 0.25 μM Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay [PMID: 33934008]
Hep 3B2 GI50 0.24 μM Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay [PMID: 33934008]
HL-60 GI50 0.59 μM Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay [PMID: 29567459]
HUVEC GI50 1.42 μM Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay [PMID: 33934008]
MCF7 GI50 0.392 μM Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 30385226]
MCF7 IC50 1.12 μM Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay [PMID: 34864330]
MDA-MB-231 GI50 0.24 μM Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay [PMID: 33934008]
MDA-MB-231 IC50 7.72 μM Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay [PMID: 34864330]
MDA-MB-468 IC50 2.52 μM Anticancer activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay [PMID: 34864330]
NCI-H1975 GI50 0.2 μM Antiproliferative activity against human NCI-H1975 cells measured after 48 hrs by SRB assay [PMID: 32683166]
NCI-H1975 GI50 0.2 μM Growth inhibition of human NCI-H1975 cells incubated for 48 hrs by SRB assay [PMID: 32058238]
NCI-H1975 GI50 0.38 μM Antiproliferative activity against human NCI-H1975 cells after 48 hrs by sulforhodamine B assay [PMID: 29567459]

20 records · Scroll to view more

BIIB021 Research Summary

This section summarizes 3 in vitro studies of BIIB021 from 1 published reference. In vitro models include isolated mouse Hsp90α N-terminal domain, residues 9–225.

BIIB021 In Vitro Studies

After 72 h, BIIB021 produced GI50 values of 0.392 ± 0.03 μM in MCF-7, 0.347 ± 0.023 μM in SK-BR-3 and 0.227 ± 0.015 μM in HCT116 cells in an MTT assay. Values were reported as means of two experiments ± SEM. These assay results describe growth inhibition and do not establish a specific cell-death mechanism. [1]

Competitive binding to human Hsp90α

Biochemical assay · Recombinant human Hsp90α N-terminal domain; FITC-geldanamycin competition assay [1]

BIIB021 displaced the fluorescent geldanamycin probe, with a reported IC50 of 0.029 μM. 17-AAG was a reference ligand.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Competition with FITC-geldanamycin for Hsp90α bindingIC50 0.029 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Ten-dose series with threefold dilution starting at 100 μM; recombinant protein 30 nM and FITC-GM probe 5 nM.
Exposure duration
30 min compound preincubation; 3 h after probe addition at room temperature.
Method
Fluorescence polarization competition assay.
Vehicle
Assay buffer contained 1% DMSO; compound stocks delivered in DMSO.
Reported limits
Exact SD and individual replicate values not provided. IC50 is assay-dependent and is not a recommended treatment concentration.
Methods and source locations

Compound reported in the paper: BIIB021; Compound label in the paper: BIIB021 reference compound

Evidence for the named BIIB021 molecule under the reported assay conditions; no source-lot equivalence or supplier validation implied.

Section 2.2.1; Table 1, BIIB021 IC50 column and footnote b; Section 3.2.1 (FITC-GM assay)

Competition with FITC-geldanamycin for Hsp90α binding: Fluorescence polarization; mean of two independent experiments; reported SD <20%, exact SD not given. — Table 1, BIIB021 IC50 column and footnote b; Section 3.2.1

Direct binding to the mouse Hsp90α N-terminal domain

Biochemical assay · Isolated mouse Hsp90α N-terminal domain, residues 9–225 [1]

Isothermal titration calorimetry measured direct BIIB021 binding to the isolated domain at 25 °C.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Equilibrium binding to mouse Hsp90α N-terminal domainKD 0.0083 µM[1]
Fitted ligand-to-protein binding stoichiometryN 0.87[1]

Literature-Reported Treatment Conditions

Treatment concentration
Protein in cell: 10–20 μM; BIIB021 in syringe: 200 μM.
Exposure duration
20 injections at 150 s intervals.
Method
ITC at 25 °C; buffer-only dilution correction and one-site model; 17-AAG reference ligand.
Vehicle
20 mM Tris, pH 8.0, 100 mM NaCl, up to 2% DMSO.
Reported limits
Replicate count and KD uncertainty are not specified for this row. The isolated mouse domain result does not establish cellular potency or isoform selectivity.
Methods and source locations

Compound reported in the paper: BIIB021; Compound label in the paper: BIIB021 reference compound

Evidence for the named BIIB021 molecule under the reported assay conditions; no source-lot equivalence or supplier validation implied.

Section 2.3.1; Table 3, BIIB021 row; Figure 4, BIIB021 panel; Sections 3.3.1 (model identity only) and 3.3.2

Equilibrium binding to mouse Hsp90α N-terminal domain: Isothermal titration calorimetry at 25 °C, buffer-alone dilution subtraction, one-site binding fit. — Table 3, BIIB021 row; Section 3.3.2

Fitted ligand-to-protein binding stoichiometry: One-site fit of ITC data. — Table 3, BIIB021 row; Section 3.3.2

Growth inhibition across three human cancer cell lines

Cell-based study · MCF-7 and SK-BR-3 breast cancer cells; HCT116 colorectal cancer cells [1]

In a 72 h MTT assay, BIIB021 showed submicromolar GI50 values in all three tested cell lines.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MCF-7 cell growth inhibitionGI50 0.392 ± 0.03 μM[1]
SK-BR-3 cell growth inhibitionGI50 0.347 ± 0.023 μM[1]
HCT116 cell growth inhibitionGI50 0.227 ± 0.015 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
72 h
Method
MTT assay; BIIB021 and 17-AAG were reference compounds in the same cell panel.
Reported limits
Exact GI50 concentration series, treatment vehicle and vehicle-control composition are not specified in the selected main-text methods. The separate 10 μM screen is not a recommended concentration.
Methods and source locations

Compound reported in the paper: BIIB021; Compound label in the paper: BIIB021 reference compound

Evidence for the named BIIB021 molecule under the reported assay conditions; no source-lot equivalence or supplier validation implied.

Section 2.2.2; Table 2, BIIB021 row and footnotes a/c; Section 3.2.2

MCF-7 cell growth inhibition: 72 h MTT assay; mean of two experiments ± SEM. — Table 2, BIIB021/MCF-7 GI50 cell and footnote c; Section 3.2.2

SK-BR-3 cell growth inhibition: 72 h MTT assay; mean of two experiments ± SEM. — Table 2, BIIB021/SK-BR-3 GI50 cell and footnote c; Section 3.2.2

HCT116 cell growth inhibition: 72 h MTT assay; mean of two experiments ± SEM. — Table 2, BIIB021/HCT116 GI50 cell and footnote c; Section 3.2.2

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 848695-25-0
Applications HSP90 inhibitor
Formula C14H15ClN6O
Molecular Weight 318.8
Synonyms CNF2024
SMILES
CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 60 mg/mL (188.22 mM)
Water Insoluble
Ethanol 2 mg/mL (6.27 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BIIB021 Research References

  1. [1] Shin SC, El-Damasy AK, Lee JH, et al. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90 International journal of molecular sciences (2020). PMID: 33317068 DOI: 10.3390/ijms21249377 Source material

Publications

7 publications citing this product

  1. Nazan Gökşen Tosun, .et al. , Breast Cancer Res Treat, 2025, Apr;210(2):493-506 PMID: 39779635
  2. Aydemir Asdemir, .et al. , Naunyn Schmiedebergs Arch Pharmacol ., 2024, Jan 19 PMID: 38240781
  3. Celia Rouges, .et al. , Microorganisms, 2023, Nov 22;11(12):2837 PMID: 38137982
  4. C M Güven, .et al. , Eur Rev Med Pharmacol Sci, 2023, Aug;27(15):7299-7308 PMID: 37606138
  5. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  6. Ting-Yu Chang, .et al. , Biomed Pharmacother, 2021, Jun;138:111485 PMID: 33740521
  7. Hiroki Murano, .et al. , Plant Biotechnol Rep, 2017, 11:107-113

Added to your cart

View Cart Checkout
Loading...